PPARA and metabolic dysfunction-associated steatohepatitis: Lanifibranor, saroglitazar, bezafibrate, and pemafibrate can contribute as immediate anti-NASH therapeutics or be lead compounds of PPAR selective agonists or pan agonists for various metabolic diseases.